

Protalix BioTherapeutics, Inc.
Form 8-K
May 02, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 1, 2012

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida 001-33357 65-0643773
(State or other jurisdiction (Commission File Number) (IRS Employer

of incorporation)

Identification No.)

2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices) **(Zip Code)**

20100

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On May 1, 2012, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that the United States Food and Drug Administration ("FDA") approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. Also on May 1, 2012, the Company issued a second press release announcing that the Company has scheduled a conference call and webcast for Wednesday, May 2 at 8:00 AM EDT to review the FDA's approval of ELELYSO™ and that a second conference call, in Hebrew, is scheduled also on Wednesday at 9:45 AM EDT (4:45 PM IDT). Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated May 1, 2012.

99.2 Press release dated May 1, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS,
INC.**

Date: May 2, 2012 By: /s/ David Aviezer
Name: David Aviezer, Ph.D.
Title: President and Chief Executive
 Officer